ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NEUP / forecast
MRKR (35) AEON (46) RADX (46) PBM (46) ⌘ Pro Terminal →

Neuphoria Therapeutics Inc. (NEUP) 12-Month Stock Forecast & Price Target Cone

$3.04 -0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.03

Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEUP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.04 (-0.33% 1D, market cap $16.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NEUP ranks #773 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEUP compare to MRKR and AEON in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEUP?
▼

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue (-68.8% YoY), -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.03 (-0.25%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$6 Bull$3 Base$2 Bear
📬 FREE NEUP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEUP)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY NEUP SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($77.2K FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$3.39+0% Next Q
Q2 (-2Q)
36
Grade E$3.39+0% Next Q
Q3 (-1Q)
34
Grade E$3.39-10.3% Next Q
Current
31
Grade E$3.04-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEUP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEUP currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.54) and Max Pain ($3.19) forces dealer call-delta covering toward $5.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEUP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NEUP Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NEUP Position Size: $10,000

Shares at $3.04: 3289.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.08
$6,842
$-3,158 (-31.6%)
12M Consensus BaseTarget $2.67
$8,783
$-1,217 (-12.2%)
12M Bull Case BreakoutTarget $5.81
$19,112
+$9,112 (+91.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$569%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEUP)

  • ✓Walkthrough of NEUP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NEUP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.53%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.06H $3.06L $3.04C $3.04VOL 70.3K
RES: $3.48SUP: $2.98SMA50: $3.54SMA200: $4.15
$6.90$5.85$4.80$3.75$2.70RES $3.48SUP $2.98$3.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEUP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEUP Butterfly Map → + Track NEUP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -68.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEUP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEUP)

Health Care Rank #773 of 1015 ⚔️ MRKR vs NEUP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEUP vs. MRKR, AEON, RADX, PBM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #773 by composite RQD confidence (31/100, grade E) and #842 by equity capitalization ($16.5M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NEUP at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NEUP ACTIVE
Neuphoria Therapeutics Inc.
E 31/100 — — -11.8% -0.33% $16.5M Benchmark Subject
MRKR
Marker Therapeutics Inc.
D- 35/100 — — -35.0% -8.05% $16.3M /mrkr-vs-neup →
AEON
AEON Biopharma Inc. (Class A)
D 46/100 — — -35.0% -0.36% $16.2M /aeon-vs-neup →
RADX
Radiopharm Theranostics Limited
D 46/100 — — — -8.05% $15.6M /radx-vs-neup →
PBM
Psyence Biomedical Ltd.
D 46/100 — — — -3.93% $17.6M /pbm-vs-neup →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001191070 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (-68.8% vs. FY2024 revenue of $50.1M , and -74.6% cumulative change since FY2023) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $15.6M -$369.6K $77.2K $77.2K $36.6M —
FY2024 (FY) 2024-06-30 $50.1M -$15.5M -$14.7M -$14.7M $18.2M —
FY2023 (FY) 2023-06-30 $61.6M -$21.4M -$14.6M -$14.6M — —

3. NEUP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.04 (-0.33% 1D, market cap $16.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NEUP ranks #773 in composite RQD confidence.

How does NEUP compare to MRKR and AEON in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEUP?

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue (-68.8% YoY), -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.04 (-0.33% on volume of 52,454 shares), positioning the stock -14.12% below its 50-day simple moving average ($3.54) and -26.75% below its 200-day simple moving average ($4.15). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 0.4% percentile with a 14-day RSI of 26.1 (OVERSOLD (<32)) and an implied next-earnings move of ±8.3% ($2.79 to $3.29).

Direct Sub-Reports: NEUP RQD Cockpit NEUP 12M Forecast NEUP Earnings & Move NEUP Dividends & DRIP NEUP Insiders & 13F NEUP Whale Options NEUP Profit Sankey NEUP News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

NEUP — Neuphoria Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuphoria Therapeutics Inc. (NEUP) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.04 (-0.33% 1D, market capitalization $16.5M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -11.8%, gross margin of —, operating margin of -7.2%, and free cash flow yield of 0.47%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neuphoria Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..0B on a rounded basis, and the market data reports $16.6M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported $15.6M in annual revenue (up from $50.1M in FY2024, -68.8% YoY) and -$369.6K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($61.6M revenue, -$21.4M net income) through FY2025, NEUP scaled operating cash flow to $77.2K and free cash flow to $77.2K, backed by $36.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.47% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.03 – $5.53 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations are therefore — The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations and a beta of 1.0. No 2nd-order bottlenecks can be identified from the source data.

  • Key Question #1: Can NEUP sustain or expand its -7.2% operating margin and -11.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $15.6M and free cash flow of $77.2K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NEUP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEUP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuphoria Therapeutics Inc. (NEUP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEUP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEUP Bull vs. Bear Conversation Board — What's Your Call at $3.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEUP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NEUP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.66 (+20.0%)
📌 Pinned Debate

FY 2025 revenue of $15.6M and positive FCF of $0.1M, with cash rising to $22.2M, mark a clear improvement from the FY 2024 net loss of

Long NEUP at $3.05 targeting $3.66. FY 2025 revenue of $15.6M and positive FCF of $0.1M, with cash rising to $22.2M, mark a clear improvement from the FY 2024 net loss of -$15.5M.. Institutional whale score is 3/20 and the risk/reward vs. the $3.03 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — NEUP's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.59 (-15.1%)
Spot @ $3.05

An RQD score of 31 (grade E) with an Altman Z-Score of 0.2 and ROIC of -11.8% signals forensic balance-sheet and cash-generation risk.

Sitting on the sidelines or leaning short NEUP above $3.05. An RQD score of 31 (grade E) with an Altman Z-Score of 0.2 and ROIC of -11.8% signals forensic balance-sheet and cash-generation risk.. Until Fundamental Cash Engine (8/20) and FCF yield (0.47%) inflect higher, upside is capped near $5.53.

LIVE TAPE